Strides gets USFDA nod to market generic cancer injection

16 Nov 2011 Evaluate

Drug firm Strides Arcolab has received approval from the UShealth regulator to market a generic carboplatin injection for the treatment ofovarian cancer. Onco Therapies, a wholly-owned subsidiary of the company, hasreceived United States Food and Drug Administration (USFDA) approval forCarboplatin injections. The approval by the USFDAis for carboplatin injections in strengths of 10 mg/mL, packaged in 50 mg/5 mL,150 mg/15 mL, 450 mg/45 mL and 600 mg/60 mL multi-dose vials. Carboplatinis part of the oncology portfolio licensed to Pfizer in January, 2010, for theUS market and is expected to be launched shortly. Accordingto IMS data of June 11, the US market for generic carboplatin is worth nearly$35 million.

Strides Pharma Scien Share Price

683.20 -1.10 (-0.16%)
23-Dec-2024 11:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.65
Dr. Reddys Lab 1350.30
Cipla 1482.65
Lupin 2184.20
Zydus Lifesciences 977.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.